Career Opportunity: Vice President, Global Specialty Development, NDD, Teva

39 0

teva_cns_logoVice President, Global Specialty Development, NDD

The Role

The Vice President, Global Clinical Development, NDD will report directly to the Vice President, Global Head, NDD/MDS & Clinical Research Innovation within the global R&D function, overseeing the clinical development of Huntington’s Disease. This is a critical role within the company, having a significant impact in defining the clinical development strategy at a high level.

The outstanding individual sought will need to be of the highest caliber medically and scientifically, with exceptional leadership capacity and interpersonal skills and the ability to work in a dynamic and truly global company that is growing rapidly. This means flexibility, taking initiative, thinking “on the fly”; a desire to be very hands-on, decisive, and self-assured are critical.

More specifically, the Vice President will be responsible for providing scientific/medical leadership and support for Huntington’s disease products now going into phase III development programs as well as looking to develop the early pipeline. There are several regulatory filings on the horizon; this individual will provide leadership and guidance throughout the process. With the addition of several new DRUG/COMPOUNDS to the NDD pipeline, the visibility of the portfolio has been elevated and the new Vice President will be a very important part of the company’s near and long-term future.

Close collaboration with Key Opinion Leaders in the Huntington’s disease market and with Teva’s Commercial and Medical Affairs groups will be critical. The new Vice President will have significant leadership responsibilities, s/he will have be an essential member of the senior management team to develop the overall strategy for the franchise and provide scientific leadership to motivate, retain and develop the group.

The clinical development department is highly team-oriented. Trust and respect is paramount, voicing opinions and thinking outside the box in a professional and appropriate scientific/medical manner is encouraged. Decisions are made as a team and the group’s culture is one that understands there is no “only” way to do things. Hard work and critical thinking are highly valued and expected. The NDD/MDS franchise is critically important to the success of Teva as a whole.

Key responsibilities include:

  • Lead and develop the Huntington’s disease clinical development program for compounds in late phase global clinical development. This includes direct oversight and management of the clinical development trials and compounds.
  • Responsible for developing the overall clinical strategy for the Huntington’s disease franchise and provide medical and scientific support to current and future commercialized products.
  • Responsible for Global Clinical Development Phase II/III trial activities and in protocol development, study execution and interpretation of results.
  • Close collaboration with Teva Global Medical Affairs and strong relationships with Key Opinion Leaders in the Huntington’s disease space.
  • Help develop the commercial strategy for compounds in late phase clinical development and attend sales meetings and other commercial meetings/activities as needed.
  • Interface effectively with other Clinical Development functions and other departments, including Clinical Operations, Biometrics in design and conduct of the clinical programs.
  • Work closely with Marketing, Medical Affairs, Regulatory Affairs and Pharmacovigilance in development of clinical plans that meet both regulatory and commercial needs.
  • Highly important member of the Vice President’s management team; makes go/no go decisions on the pipeline and key decision maker in what the company does in Huntington’s Disease in the present and future.
  • Create and maintain a positive and productive work environment and exhibit exceptional leadership capabilities by creating trust and respect within Huntington’s Disease clinical development as with other colleagues in Teva.
  • Need to support critical evaluations and recommendations of business development opportunities in the respiratory area working with colleagues from the Search and Evaluation Team and business development.

Candidate Profile

The ideal candidate will demonstrate the following qualifications and competencies:

  • M.D., Board Certified (Neurology, Psychiatry, etc.) or Clinical Geneticist with Strong Clinical Knowledge of Huntington’s disease. (Neuroscientist or Neurology or Psychiatry.) Minimum of 10 years’ experience in a clinical development function within a biotech or pharmaceutical company.
  • Outstanding proven track record in Huntington’s disease drug development; intimate understanding of Huntington’s disease a must.
  • Experience filing multiple New Drug Applications (NDA’s) preferred.
  • Strong relationships with Huntington’s disease Key Opinion Leaders (KOL’s) across the country and globe.
  • Well-developed leadership skills with the ability to influence, able to make decisions and stand by them. This individual will be highly visible at all levels of the organization and must be able to build trust and credibility walking in the door.
  • Exceptionally sharp thinker; ability to push innovation and creative thinking. Strategic thinking, accountable and forward-looking; able to see larger business picture.
  • Flexible, work in a fast-paced environment and be open to change or the unknown.
  • Collaborative and proactive, with a hands-on, roll-up-the-sleeves style and attitude.
  • Excellent interpersonal, presentation and communication skills.
  • If interested, please call/send CV to:

Al DiPalo
Sr. Strategic Sourcing Partner
Teva Pharmaceuticals
267-619-2132
Mauro.dipalo@tevapharm.com

Leave a comment

Your email address will not be published. Required fields are marked *

Related Post

Animal Models of HD

September 1, 2014 0
A critical tool in the quest for treatments By: Mahmoud A. Pouladi, PhD Our current understanding of the pathological processes…

Meet the Investigator

September 1, 2011 0
VITAL SIGNS NAME: Sarah Tabrizi CURRENT POSITION: Professor of Clinical Neurology at University College London EDUCATION: PhD Biochemistry University College…

Meet the Company

September 1, 2012 0
        VITAL SIGNS NAME: Isis Pharmaceuticals HEADQUARTERS: Carlsbad, California STOCK PRICE AS OF 8/21/12: $13.67 52 WEEK…

Highlights of CHDI

June 16, 2016 0
By: Lise Munsie, PhD CHDI began this year’s conference with a pre-session where members discussed what was happening at the…